Aug 2026· Development, Growth and Differentiation· Vol 68· 0 citations· 71 references
Medicine
TL;DR
The criteria for direct lineage reprogramming, atypical pluripotent reprogramming and noncanonical pluripotent reprogramming are delineated, and novel approaches like bacterial ribosome‐mediated cell fate conversion are explored like bacterial ribosome‐mediated cell fate conversion.
Abstract
The traditional hierarchical view of totipotent cells generating diverse lineages of terminally differentiated cells was challenged by the discovery of induced pluripotent stem cells (iPSCs). This breakthrough demonstrated that the ectopic expression of four transcription factors, Oct4, Sox2, Klf4, and c‐Myc (OSKM), can reprogram somatic cells to a pluripotent state. Since then, studies have expanded into diverse reprogramming strategies employing different cell types, factor combinations, delivery methods, and microenvironmental cues, resulting in the generation of diverse pluripotent and multipotent states. iPSCs modeled as canonical pluripotent reprogramming are defined by a core transcriptional network, the capacity for tri‐lineage differentiation, and a permissive epigenetic landscape. However, growing evidence has revealed other reprogramming trajectories, including direct lineage reprogramming (or transdifferentiation), atypical pluripotent reprogramming, and noncanonical pluripotent reprogramming—exemplified as bacterial protein‐mediated multipotency. Here, we summarize emerging insights of canonical and alternative pluripotent reprogramming strategies to propose a more nuanced framework that views pluripotency as a spectrum of molecular and functional states. These unconventional states often exhibit incomplete erasure of somatic identity, altered regulatory networks, and restricted lineage potential, underscoring the plastic and context‐dependent nature of pluripotency. This review aims to reconceptualize fundamental perspectives on the acquisition of pluripotency in mammalian fibroblasts based on recent advances. We delineate the criteria for direct lineage reprogramming, atypical pluripotent reprogramming and noncanonical pluripotent reprogramming, explore novel approaches like bacterial ribosome‐mediated cell fate conversion. This study integrates these strategies into a unified resource to enhance conceptual clarity and establishes a platform for advancing regenerative medicine.
It is demonstrated that coordinated regulation of both cytosolic and mitochondrial translation during totipotent-like reprogramming is offered, offering a new perspective for understanding cell fate determination.
Lingci Huang, Jun Zhang, Xin-Wei Wu et al.· Journal of Biological Chemis...· 0 citations
These findings establish IRAK4 as a regulator that constrains cellular plasticity potentially by coordinating chromatin accessibility and cell cycle dynamics, which may facilitate the establishment of multi-lineage states.
Chuanshu Huang, Xiao-Yun Han, Tao Wang et al.· EMBO Reports· 0 citations
Recognising the central role of VSELs/progenitors and their niche in maintaining tissue homeostasis in vivo could resolve existing roadblocks and guide more effective endogenous regenerative therapies for diseased tissues and age-related dysfunctions.
D. Bhartiya, N. Sharma, Anish Tripathi et al.· Stem Cell Reviews and Report...· 0 citations
This review summarizes the trajectory of iPSC reprogramming technologies and identifies the core “translational triltrilas”, namely, the inherent tradeoffs between security, homogeneity, and scalability, and proposes a comprehensive strategy to overcome these bottlenecks.
Meng-Meng Chen, N. Zuo, Qi Wang et al.· Frontiers in Cell and Develo...· 0 citations
This Review evaluates the technological and translational trajectories that have defined the iPSC era and analyzes the operational barriers to therapeutic development, envisioning a paradigm shift in which iPSC-derived interventions transition from bespoke experimental models toward standardized, engineered biological...
Jaecheol Lee, Todd J. Herron, L. Studer et al.· Nature Medicine· 0 citations
Key applications of iPSC technology in hemato-oncology are summarized, its major advantages and current limitations are discussed, and emerging directions are highlighted, including scalable iPSC-derived blood cell therapies for inherited and acquired bone marrow failure syndromes and leukemia.
Ivan Tesakov, M. Nasri, M. Klimiankou et al.· Frontiers in Immunology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.